Davidson Kempner Capital Management’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

Davidson Kempner Capital Management’s Portfolio PKBO Stock Details PKBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-225,229	Closed	-$2.25M	–	497
2022 Q3	$2.25M	Hold	225,229	–	–	0.04%	293
2022 Q2	$2.22M	Hold	225,229	–	–	0.04%	300
2022 Q1	$2.22M	Hold	225,229	–	–	0.03%	336
2021 Q4	$2.19M	Hold	225,229	–	–	0.03%	320
2021 Q3	$2.2M	Buy	225,229 +49,020	+28%	+$475K	0.03%	278
2021 Q2	$1.71M	Buy	+176,209	New	+$1.72M	0.01%	358

Other funds holding PKBO

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Davidson Kempner Capital Management's PKBO Position: Q4 2022 in Review

Davidson Kempner Capital Management sold out of Peak Bio, Inc. Common Stock (PKBO) in Q4 2022, closing a stake of 225,229 shares — an estimated $2.25M sold.

Davidson Kempner Capital Management first reported a position in PKBO in Q2 2021 and held it in 6 quarters. The position peaked at $2.25M in Q3 2022. 9 funds tracked by Wall St. Rank hold PKBO as of Q4 2022.

Davidson Kempner Capital Management reported no remaining Peak Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Davidson Kempner Capital Management sold 225,229 Peak Bio, Inc. Common Stock shares in Q4 2022, an estimated $2.25M.
Davidson Kempner Capital Management first reported a position in Peak Bio, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Davidson Kempner Capital Management's Peak Bio, Inc. Common Stock position peaked at $2.25M in Q3 2022.
9 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q4 2022.

Based on Davidson Kempner Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.